SLC5A2 and diabetes mellitus: While use of these therapies was higher in those with DM who had multiple risk factors or ASCVD compared to those without multiple risk factors, even in those with both DM and ASCVD, only 8.6% were on an SGLT2-i and 11.9% on a GLP-1 RA.